Therapy with the CAR-T cell remedy Yescarta (axicabtagene ciloleucel) continued to reveal sturdy responses after a median follow-up of greater than 5 years in sufferers with relapsed/refractory indolent non-Hodgkin lymphoma, together with follicular lymphoma, based on knowledge from the part 2 ZUMA-5 trial. Notably, these knowledge have been shared in a presentation from investigators on the 2024 American Society of Hematology Annual Assembly.
Glossary
CAR T-cell remedy: a sort of most cancers immunotherapy the place a affected person’s personal T cells are genetically engineered in a lab, permitting them to particularly acknowledge and kill most cancers cells when reinfused again into the affected person.
Dr. Sattva S. Neelapu mentioned the outcomes of the medical trial in an interview with CURE® on the assembly, delving into insights on the trial, in addition to the potential challenges and limitations of CAR-T cell remedy on this affected person inhabitants, in addition to how these challenges are being addressed in ongoing analysis.
Neelapu is a professor and deputy division chair within the Division of Lymphoma/Myeloma, Division of Most cancers Medication, at The College of Texas MD Anderson Most cancers Heart, in Houston, in addition to a member of Graduate College, Immunology Program, Graduate College of Biomedical Sciences, at The College of Texas Well being Science Heart, additionally situated in Houston.
Wish to hear extra from Neelapu? Learn our full interview with him right here!
Transcript:
One potential limitation of CAR-T cell remedy normally is that it’s accessible solely at restricted variety of facilities. At present, there are roughly 125 facilities that administer CAR-T cell remedy. [Therefore], it does require sufferers to journey to a CAR-T heart to have the ability to obtain this remedy, and so they usually want to remain within the space for a few five-week interval, together with the caregiver, ideally. Often, a part of the keep might be within the hospital, however throughout the remainder of the time, they’re monitored within the outpatient unit.
That is one limitation, and the opposite limitation is as a result of it is a patient-specific remedy, value is certainly a limitation. Though it is an FDA-approved indication, at the moment, so it’s lined by most insurances, in addition to Medicare and Medicaid.
Transcript was edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
